To find better ways to tackle cancer tumors that do not respond to traditional therapies, scientists are now experimenting with a modified bacterial strain that could target cancer cells without harming healthy ones. A phase I clinical trial reveals that this bacterial therapy shows promising effects.
A team at the University of Texas MD Anderson Cancer Center in Houston is now assessing the safety and usefulness of bacterial therapy for treating cancer tumors that don’t respond to other types of treatment.
The findings so far – recently presented at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, held in New York City, NY – suggest that the therapy has manageable toxicity levels and can help shrink some resilient cancer tumors.
“Even after a single injection of this bacterial therapy, we see biological and, in some patients, clinically meaningful activity,” explains study co-author Dr. Filip Janku.